India, Nov. 13 -- Shares of Amneal Pharmaceuticals Inc. (AMRX) hit a new 52-week high yesterday, buoyed by improving financial performance and another upward revision to its 2026 guidance. With momentum building across its business, the company is positioning itself for further growth in 2027, supported by key catalysts and new product launches.
Headquartered in Bridgewater, New Jersey, Amneal Pharmaceuticals has a portfolio of about 300 generic, specialty and biosimilar medicines and supplies more than 160 million prescriptions annually, mainly in the U.S. Its business has three segments: Affordable Medicines, which includes generic drugs, injectables and biosimilars; Specialty, which focuses on branded treatments for neurological conditi...